
35. The use of claim 34 further comprising one or more HIV antiviral agent selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.

36. The compound



or a pharmaceutically acceptable salt thereof.

37. A pharmaceutical composition comprising an effective amount of the compound according to claim 36, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

38. The pharmaceutical composition of claim 37 further comprising one or more HIV antiviral agent selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.

39. Use of the compound according to claim 36, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS in a subject in need thereof.

40. The ~~method~~ use of claim 39 further comprising one or more HIV antiviral agent selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.